Savin V - Search Results

1

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Joy MS, et al. Among authors: savin v. Am J Kidney Dis. 2010 Jan;55(1):50-60. doi: 10.1053/j.ajkd.2009.08.019. Epub 2009 Nov 22. Am J Kidney Dis. 2010. PMID: 19932542 Free PMC article. Clinical Trial.

2

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

Peyser A, Machardy N, Tarapore F, Machardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H. Peyser A, et al. Among authors: savin v. BMC Nephrol. 2010 Jan 29;11:2. doi: 10.1186/1471-2369-11-2. BMC Nephrol. 2010. PMID: 20113498 Free PMC article. Clinical Trial.

3

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.

Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T. Trachtman H, et al. Among authors: savin v. BMC Nephrol. 2011 Feb 10;12:8. doi: 10.1186/1471-2369-12-8. BMC Nephrol. 2011. PMID: 21310077 Free PMC article. Clinical Trial.

4

Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis.

Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ. Cattran D, et al. J Am Soc Nephrol. 2003 Feb;14(2):448-53. doi: 10.1097/01.asn.0000046960.57614.17. J Am Soc Nephrol. 2003. PMID: 12538746 Clinical Trial.

5

Glomerular permeability activity: prevalence and prognostic value in pediatric patients with idiopathic nephrotic syndrome.

Trachtman H, Greenbaum LA, McCarthy ET, Sharma M, Gauthier BG, Frank R, Warady B, Savin VJ. Trachtman H, et al. Am J Kidney Dis. 2004 Oct;44(4):604-10. Am J Kidney Dis. 2004. PMID: 15384010

6

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.

Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS. Trachtman H, et al. BMC Nephrol. 2015 Jul 22;16:111. doi: 10.1186/s12882-015-0094-5. BMC Nephrol. 2015. PMID: 26198842 Free PMC article. Clinical Trial.

7

Galactose treatment in focal segmental glomerulosclerosis.

Trachtman H, Savin VJ. Trachtman H, et al. Pediatr Nephrol. 2014 May;29(5):931. doi: 10.1007/s00467-013-2700-8. Epub 2013 Dec 22. Pediatr Nephrol. 2014. PMID: 24362723 Free PMC article. No abstract available.

8

Circulating factor in patients with recurrent focal segmental glomerulosclerosis postrenal transplantation inhibits expression of inducible nitric oxide synthase and nitric oxide production by cultured rat mesangial cells.

Trachtman H, Futterweit S, Singhal PC, Franki N, Sharma M, Sharma R, Savin V. Trachtman H, et al. Among authors: savin v. J Investig Med. 1999 Mar;47(3):114-20. J Investig Med. 1999. PMID: 10198566

9

Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys.

Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, Hirschberg R, Adler SG. Feld SM, et al. Among authors: savin v. Am J Kidney Dis. 1998 Aug;32(2):230-7. doi: 10.1053/ajkd.1998.v32.pm9708606. Am J Kidney Dis. 1998. PMID: 9708606

10

Proteinuria after injection of human focal segmental glomerulosclerosis factor.

Sharma M, Sharma R, Reddy SR, McCarthy ET, Savin VJ. Sharma M, et al. Transplantation. 2002 Feb 15;73(3):366-72. doi: 10.1097/00007890-200202150-00009. Transplantation. 2002. PMID: 11884932

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page